Porto public hospital offering clinical trial site capacity in oncology imaging AI and COVID-19 vaccine research across European consortia.
ULSSA (formerly known as Hospital de Santo António) is a major public hospital complex in Porto, Portugal, providing tertiary-level clinical care across oncology, infectious disease, and diagnostic imaging. In EU research projects, they function as a clinical trial site — contributing patient cohorts, medical imaging data, and regulated clinical infrastructure rather than conducting laboratory or computational research. Their H2020 participation reflects two distinct hospital capabilities: a radiology and oncology service capable of generating MRI and CT imaging datasets for AI model training, and an infectious disease and vaccinology unit equipped to run Phase II/III clinical vaccine trials under standardized European protocols.
In CHAIMELEON, ULSSA contributed clinical imaging data (MRI, CT) and patient cohorts across lung, breast, colorectal, and prostate cancers to support AI tool development and regulatory compliance workflows.
In VACCELERATE, ULSSA served as a mapped and capacitated clinical site within Europe's COVID-19 vaccine trial accelerator network, supporting data standardisation and single entry-point trial access.
CHAIMELEON required participating hospitals to have multi-cancer clinical workflows and image repositories, indicating ULSSA has structured oncology data and regulatory-compliant processes in place.
VACCELERATE included site mapping and capacity building, suggesting ULSSA was assessed and validated as a pandemic-ready clinical trial facility within the European network.
ULSSA entered H2020 research through oncology and diagnostic imaging — specifically contributing to AI-driven cancer management tools built on radiology datasets (MRI, CT) and multi-cancer biomarker pipelines. Their second project shifted entirely to infectious disease and vaccine trial infrastructure, driven by the COVID-19 emergency. This is not a gradual evolution in research focus but a parallel demonstration of two distinct hospital departments engaging with EU-funded research independently. The clearest trend is that ULSSA is building a record as a multi-purpose clinical trial site rather than deepening expertise in any single disease area.
ULSSA appears to be positioning itself as a validated, multi-indication European clinical trial site — making it a candidate for future consortia that need Portuguese hospital access, regulated patient data, or GCP-compliant trial capacity across oncology or infectious disease.
ULSSA has participated exclusively as a partner, never taking on project coordination — consistent with a hospital that contributes clinical infrastructure and patient access rather than scientific leadership or administrative management. Both their projects were large-scale RIA consortia, and their 50 unique partners across just 2 projects signals they operate in broad, multi-site networks rather than tight bilateral collaborations. This makes them a reliable and low-friction partner for consortia that need distributed clinical sites across European member states.
Despite only two H2020 projects, ULSSA has built connections with 50 unique consortium partners across 23 countries — an unusually wide network for an organization at this participation level, reflecting the large multi-hospital structures typical of pan-European clinical trial platforms. Their network is broad and European in character, with no evident regional concentration.
ULSSA is one of the few Portuguese hospital units with documented involvement in both AI-driven oncology imaging research and COVID-19 vaccine trial networks, giving it a dual clinical profile that is rare among Portuguese public health institutions. For consortium builders needing a Southern European clinical site with multi-cancer imaging capacity and pandemic trial credentials, ULSSA fills a specific and hard-to-substitute role. Their public hospital status also means they bring access to diverse, unselected patient populations — a key advantage for studies requiring representative clinical data.
